Summary

The first prospective, multicenter, randomized Phase 2 study to test the use of customized chemotherapy (CT) in locally advanced stage IIIA (N2) non—small cell lung cancer (NSCLC) is currently recruiting patients. The rationale and design of the Customized Neoadjuvant Versus Standard Chemotherapy in NSCLC Patients With Resectable Stage IIIA (N2) Disease trial [CONTEST; NCT01784549] were presented in a poster session.